Meredith C Meacham1, Danielle E Ramo2, Alex H Kral3, Elise D Riley4. 1. Department of Psychiatry and Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA. Electronic address: meredith.meacham@ucsf.edu. 2. Department of Psychiatry and Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA. 3. RTI International, San Francisco, CA, USA. 4. Division of HIV, Infectious Disease & Global Medicine, University of California, San Francisco, CA, USA.
Abstract
BACKGROUND: Several studies suggest that U.S. state-level legalization of cannabis for medical purposes may be associated with reductions in opioid use; yet its relationship with stimulant use, particularly in high-risk populations like unstably housed women, has received less attention. The purpose of this study was to estimate independent associations between medical and non-medical use of cannabis and use of stimulants and opioids among unstably housed women. METHODS: Cross-sectional data were analyzed from 245 women in the SHADOW study, a community based cohort in San Francisco, CA, in which HIV+ women were oversampled (126 HIV+ and 119 HIV-). RESULTS: Compared to no cannabis use in the past 6 months (51%), non-medical cannabis use (28%) was associated with a higher adjusted odds of using stimulants (Adjusted Odds Ratio [AOR]=4.34, 95% confidence interval [CI]: 2.17-8.70) and opioids (AOR=3.81, 95% CI: 1.78-8.15). Compared to no cannabis use, medical cannabis use (21%) was not significantly associated with stimulant or opioid use. Compared to non-medical cannabis use, however, medical cannabis use was associated with lower adjusted odds of using stimulants (AOR=0.42, 95% CI: 0.18-0.96). These associations were not modified by HIV status. CONCLUSIONS: Associations between use of cannabis and "street drugs" depend on whether the cannabis is obtained through a medical context. Interventions, research, and policy considering the influence of cannabis on the use of other drugs may benefit by distinguishing between medical and non-medical cannabis use.
BACKGROUND: Several studies suggest that U.S. state-level legalization of cannabis for medical purposes may be associated with reductions in opioid use; yet its relationship with stimulant use, particularly in high-risk populations like unstably housed women, has received less attention. The purpose of this study was to estimate independent associations between medical and non-medical use of cannabis and use of stimulants and opioids among unstably housed women. METHODS: Cross-sectional data were analyzed from 245 women in the SHADOW study, a community based cohort in San Francisco, CA, in which HIV+ women were oversampled (126 HIV+ and 119 HIV-). RESULTS: Compared to no cannabis use in the past 6 months (51%), non-medical cannabis use (28%) was associated with a higher adjusted odds of using stimulants (Adjusted Odds Ratio [AOR]=4.34, 95% confidence interval [CI]: 2.17-8.70) and opioids (AOR=3.81, 95% CI: 1.78-8.15). Compared to no cannabis use, medical cannabis use (21%) was not significantly associated with stimulant or opioid use. Compared to non-medical cannabis use, however, medical cannabis use was associated with lower adjusted odds of using stimulants (AOR=0.42, 95% CI: 0.18-0.96). These associations were not modified by HIV status. CONCLUSIONS: Associations between use of cannabis and "street drugs" depend on whether the cannabis is obtained through a medical context. Interventions, research, and policy considering the influence of cannabis on the use of other drugs may benefit by distinguishing between medical and non-medical cannabis use.
Authors: Joana C M Narvaez; Karen Jansen; Ricardo T Pinheiro; Flávio Kapczinski; Ricardo A Silva; Flávio Pechansky; Pedro V Magalhães Journal: Compr Psychiatry Date: 2014-05-04 Impact factor: 3.735
Authors: Ronald J Ellis; Will Toperoff; Florin Vaida; Geoffrey van den Brande; James Gonzales; Ben Gouaux; Heather Bentley; J Hampton Atkinson Journal: Neuropsychopharmacology Date: 2008-08-06 Impact factor: 7.853
Authors: Philippe Lucas; Zach Walsh; Kim Crosby; Robert Callaway; Lynne Belle-Isle; Robert Kay; Rielle Capler; Susan Holtzman Journal: Drug Alcohol Rev Date: 2015-09-14
Authors: Laura Jean Bierut; Jaime R Strickland; Jeremy R Thompson; Stephanie E Afful; Linda B Cottler Journal: Drug Alcohol Depend Date: 2008-02-19 Impact factor: 4.492
Authors: Meredith C Meacham; Ou Stella Liang; Mengnan Zhao; Christopher C Yang; Johannes Thrul; Danielle E Ramo Journal: Nicotine Tob Res Date: 2021-01-07 Impact factor: 4.244
Authors: Jenna Valleriani; Rebecca Haines-Saah; Rielle Capler; Ricky Bluthenthal; M Eugenia Socias; M J Milloy; Thomas Kerr; Ryan McNeil Journal: Int J Drug Policy Date: 2020-04-11